What does MEDIFAR do?

MEDIFAR is a pharmacy in Meerhout. Public Limited, started on 3 January 1996, 1 establishment.

What is the address of MEDIFAR?

The registered office of MEDIFAR is located at Beerstraat 16, 2450 Meerhout.

Is MEDIFAR still active?

Yes. According to the CBE (30 October 2026) MEDIFAR is active, legal situation “Normale toestand”, started on 3 January 1996.

Is MEDIFAR registered on Peppol?

Yes, MEDIFAR is registered on the Peppol network with ID 0208:0456978480.

What is the enterprise number of MEDIFAR?

The enterprise number of MEDIFAR is BE0456978480.

When was MEDIFAR founded?

MEDIFAR was founded on 3 January 1996.

Who are the directors of MEDIFAR?

According to the 2025 annual accounts, the directors of MEDIFAR are: JAN GOVAERTS, SANDRA VANGENECHTEN, APEGO BV, PHARMA LAENEN BV.

Is MEDIFAR a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 3 January 1996; 5 annual accounts filed, latest fiscal year 2025; 4 directors known from the annual account.

How much profit did MEDIFAR make in 2025?

MEDIFAR posted a profit after taxes of € 115,474 in financial year 2025.

What is the revenue of MEDIFAR?

As a small company, MEDIFAR is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 247,744.

How much does an employee at MEDIFAR earn?

The average wage cost per full-time employee at MEDIFAR was € 39,600 in 2022: staff costs of € 39,644 for 1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does MEDIFAR have?

According to the 2025 annual accounts, MEDIFAR has 0.7 full-time equivalents (FTE).

MEDIFAR (Public Limited) - Meerhout - BE0456978480

Dossier MEDIFAR, printed on 30 October 2026 from databakkes.be/en/0456978480/medifar. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

MEDIFAR from Meerhout, company number BE0456978480, closed financial year 2025 with a result of € 115,474 after tax. For that financial year MEDIFAR recorded a gross margin of € 247,744 and equity of € 869,111. Compared with financial year 2024, the result moved from € 75,116 to € 115,474. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 8, 2026.

What it is worth Healthy

€ 869,111

▼ 3% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 115,474

▲ 54% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 333,678

▲ 60% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 146,115 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

0.7

▲ 0.2 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 29,569

▲ 16% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 39,979

▼ 35% vs 2024

Of which on lease € 14,496.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 20,824

▼ 44% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 20,532

▲ € 16,127 vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 253,560 Gross margin 2022: € 253,560 First fiscal year in the series	€ 188,996 Gross margin 2023: € 188,996 ▼ 25% vs 2022 (€ 253,560) Unfavourable step	€ 203,547 Gross margin 2024: € 203,547 ▲ 8% vs 2023 (€ 188,996) Favourable step	€ 247,744 Gross margin 2025: € 247,744 ▲ 22% vs 2024 (€ 203,547) Favourable step	▲ 22%
Profit after taxes	€ 108,192 Profit after taxes 2022: € 108,192 First fiscal year in the series	€ 89,752 Profit after taxes 2023: € 89,752 ▼ 17% vs 2022 (€ 108,192) Unfavourable step	€ 75,116 Profit after taxes 2024: € 75,116 ▼ 16% vs 2023 (€ 89,752) Unfavourable step	€ 115,474 Profit after taxes 2025: € 115,474 ▲ 54% vs 2024 (€ 75,116) Favourable step	▲ 54%
Equity	€ 734,883 Equity 2022: € 734,883 First fiscal year in the series	€ 824,636 Equity 2023: € 824,636 ▲ 12% vs 2022 (€ 734,883) Favourable step	€ 899,752 Equity 2024: € 899,752 ▲ 9% vs 2023 (€ 824,636) Favourable step	€ 869,111 Equity 2025: € 869,111 ▼ 3% vs 2024 (€ 899,752) Unfavourable step	▼ 3%
Total debts	€ 110,073 Total debts 2022: € 110,073 First fiscal year in the series	€ 128,310 Total debts 2023: € 128,310 ▲ 17% vs 2022 (€ 110,073) Unfavourable step	€ 45,333 Total debts 2024: € 45,333 ▼ 65% vs 2023 (€ 128,310) Favourable step	€ 52,744 Total debts 2025: € 52,744 ▲ 16% vs 2024 (€ 45,333) Unfavourable step	▲ 16%
Cash	€ 244,817 Cash 2022: € 244,817 First fiscal year in the series	€ 323,174 Cash 2023: € 323,174 ▲ 32% vs 2022 (€ 244,817) Favourable step	€ 208,315 Cash 2024: € 208,315 ▼ 36% vs 2023 (€ 323,174) Unfavourable step	€ 333,678 Cash 2025: € 333,678 ▲ 60% vs 2024 (€ 208,315) Favourable step	▲ 60%
Land & buildings	€ 131,907 Land & buildings 2022: € 131,907 First fiscal year in the series	€ 127,542 Land & buildings 2023: € 127,542 ▼ 3% vs 2022 (€ 131,907) Unchanged	€ 125,911 Land & buildings 2024: € 125,911 ▼ 1% vs 2023 (€ 127,542) Unchanged	€ 123,207 Land & buildings 2025: € 123,207 ▼ 2% vs 2024 (€ 125,911) Unchanged	▼ 2%
Retained profit	€ 672,883 Retained profit 2022: € 672,883 First fiscal year in the series	€ 762,636 Retained profit 2023: € 762,636 ▲ 13% vs 2022 (€ 672,883) Favourable step	€ 837,752 Retained profit 2024: € 837,752 ▲ 10% vs 2023 (€ 762,636) Favourable step	€ 807,111 Retained profit 2025: € 807,111 ▼ 4% vs 2024 (€ 837,752) Unfavourable step	▼ 4%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 146,115 Dividend 2025: € 146,115 Unchanged (€ 0) Unchanged
Bank debt	€ 35,362 Bank debt 2022: € 35,362 First fiscal year in the series	€ 15,203 Bank debt 2023: € 15,203 ▼ 57% vs 2022 (€ 35,362) Favourable step	€ 0 Bank debt 2024: € 0 ▼ 100% vs 2023 (€ 15,203) Favourable step	€ 0 Bank debt 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 844,957 Balance sheet total 2022: € 844,957 First fiscal year in the series	€ 952,946 Balance sheet total 2023: € 952,946 ▲ 13% vs 2022 (€ 844,957) Unchanged	€ 945,084 Balance sheet total 2024: € 945,084 ▼ 1% vs 2023 (€ 952,946) Unchanged	€ 921,854 Balance sheet total 2025: € 921,854 ▼ 2% vs 2024 (€ 945,084) Unchanged	▼ 2%
Employees (FTE)	1 Employees (FTE) 2022: 1 First fiscal year in the series	0.9 Employees (FTE) 2023: 0.9 ▼ 0.1 vs 2022 (1) Unchanged	0.5 Employees (FTE) 2024: 0.5 ▼ 0.4 vs 2023 (0.9) Unchanged	0.7 Employees (FTE) 2025: 0.7 ▲ 0.2 vs 2024 (0.5) Unchanged	▲ 0.2

Key figures of MEDIFAR, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to MEDIFAR?

What happened at MEDIFAR in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 8, 2026 New annual accounts for financial year 2025: profit of € 115,474 (▲ 54% vs 2024). Source: NBB ↗
2024 PHARMA LAENEN BV became a director. NBB
2018 APEGO BV became a director. NBB
Feb 23, 1996 New establishment in Meerhout. KBO
1996 JAN GOVAERTS became a director. NBB
1996 SANDRA VANGENECHTEN became a director. NBB
Jan 3, 1996 Start of the company according to the CBE. KBO

In short

From € 108,192 profit in 2022 to € 115,474 profit in 2025.

Paid € 172,039 in corporate taxes since 2022.

Best year ever: 2025, with € 115,474 profit.

On average € 253,600 of value added per employee in 2022.

Original PDFs at the National Bank ↗

Management

JAN GOVAERTS

SANDRA VANGENECHTEN

MEDIFAR

Behind MEDIFAR are JAN GOVAERTS, SANDRA VANGENECHTEN, APEGO BV and PHARMA LAENEN BV. The shares are held by JAN GOVAERTS and SANDRA VANGENECHTEN.

Directors

According to the 2025 annual accounts

JAN GOVAERTS

Managing director

Is a shareholder

Also active at: Reales

since 1996

SANDRA VANGENECHTEN

Director

Is a shareholder

since 1996

APEGO BV

Director · represented by Peter Govaerts

since 2018

PHARMA LAENEN BV

Director · represented by Leonie Laenen

since 2024

Shareholders

JAN GOVAERTS · director

SANDRA VANGENECHTEN · director

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Beerstraat 16

2450 Meerhout

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Reales same network

€ 127,357 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0456.978.480

VAT number

BE 0456.978.480

Registered office

Beerstraat 16, 2450 Meerhout

Names & denominations

MEDIFAR

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

3 January 1996

Peppol

Active · Active since 9 Jan 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

Detailhandel in cosmetica en toiletartikelen

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Detailhandel in medische en orthopedische artikelen

Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels

View on CBE Public ↗ Annual accounts (NBB) ↗

MEDIFAR

Financials

What happened to MEDIFAR?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions